1. Home
  2. AES vs GKOS Comparison

AES vs GKOS Comparison

Compare AES & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The AES Corporation

AES

The AES Corporation

HOLD

Current Price

$14.81

Market Cap

9.9B

Sector

Utilities

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$153.34

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AES
GKOS
Founded
1981
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9B
8.7B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
AES
GKOS
Price
$14.81
$153.34
Analyst Decision
Hold
Strong Buy
Analyst Count
10
12
Target Price
$15.29
$126.92
AVG Volume (30 Days)
8.2M
768.7K
Earning Date
05-01-2026
04-29-2026
Dividend Yield
4.87%
N/A
EPS Growth
N/A
N/A
EPS
0.68
N/A
Revenue
$12,233,000,000.00
$507,442,000.00
Revenue This Year
$5.22
$23.32
Revenue Next Year
$4.81
$27.43
P/E Ratio
$21.76
N/A
Revenue Growth
N/A
32.33
52 Week Low
$12.33
$73.16
52 Week High
$17.65
$161.53

Technical Indicators

Market Signals
Indicator
AES
GKOS
Relative Strength Index (RSI) 63.26 61.84
Support Level $14.57 $96.44
Resistance Level $15.02 N/A
Average True Range (ATR) 0.07 6.25
MACD 0.01 -0.15
Stochastic Oscillator 87.10 65.68

Price Performance

Historical Comparison
AES
GKOS

About AES The AES Corporation

AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: